Yuichi J Shimada1, Jonathan J Passeri2, Aaron L Baggish2, Caitlin O'Callaghan2, Patricia A Lowry2, Gia Yannekis2, Suhny Abbara3, Brian B Ghoshhajra3, Richard D Rothman2, Carolyn Y Ho1, James L Januzzi2, Christine E Seidman4, Michael A Fifer5. 1. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 3. Cardiac MR PET CT Program, Department of Radiology and Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 4. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Howard Hughes Medical Institute, Boston, Massachusetts; Department of Genetics, Harvard Medical School, Boston, Massachusetts. 5. Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: mfifer@partners.org.
Abstract
OBJECTIVES: The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM). BACKGROUND: Despite evidence that myocardial hypertrophy and fibrosis are mediated by angiotensin II and are important determinants of morbidity and mortality in patients with HCM, no prior studies have evaluated the effects of angiotensin receptor blockers on LV hypertrophy and fibrosis with cardiac magnetic resonance imaging. METHODS: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n = 9) or losartan 50 mg twice a day (n = 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. RESULTS: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]: +5% [-4% to +21%] with placebo vs. -5% [-11% to -0.9%] with losartan; p = 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31% ± 26% with placebo vs. -23% ± 45% with losartan; p = 0.03). CONCLUSIONS: This pilot study suggests attenuation of progression of myocardial hypertrophy and fibrosis with losartan in patients with nonobstructive HCM. Confirmation of these results in a larger trial is required to confirm a place for angiotensin receptor blockers in the management of patients with HCM. (Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy; NCT01150461).
OBJECTIVES: The aim of this study was to evaluate the effects of losartan on left ventricular (LV) hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy (HCM). BACKGROUND: Despite evidence that myocardial hypertrophy and fibrosis are mediated by angiotensin II and are important determinants of morbidity and mortality in patients with HCM, no prior studies have evaluated the effects of angiotensin receptor blockers on LV hypertrophy and fibrosis with cardiac magnetic resonance imaging. METHODS: In double-blind fashion, 20 patients (3 women, 17 men; age: 51 ± 13 years) with HCM were randomly assigned to receive placebo (n = 9) or losartan 50 mg twice a day (n = 11) for 1 year. Cardiac magnetic resonance imaging was performed at baseline and 1 year to measure LV mass and extent of fibrosis as assessed by late gadolinium enhancement. RESULTS: There was a trend toward a significant difference in the percent change in LV mass (median [interquartile range]: +5% [-4% to +21%] with placebo vs. -5% [-11% to -0.9%] with losartan; p = 0.06). There was a significant difference in the percent change in extent of late gadolinium enhancement, with the placebo group experiencing a larger increase (+31% ± 26% with placebo vs. -23% ± 45% with losartan; p = 0.03). CONCLUSIONS: This pilot study suggests attenuation of progression of myocardial hypertrophy and fibrosis with losartan in patients with nonobstructive HCM. Confirmation of these results in a larger trial is required to confirm a place for angiotensin receptor blockers in the management of patients with HCM. (Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy; NCT01150461).
Keywords:
angiotensin II receptor blocker; cardiac magnetic resonance imaging; hypertrophic cardiomyopathy; late gadolinium enhancement; left ventricular fibrosis
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Caitlin J Harrigan; Dana C Peters; C Michael Gibson; Barry J Maron; Warren J Manning; Martin S Maron; Evan Appelbaum Journal: Radiology Date: 2010-11-02 Impact factor: 11.105
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Eur J Heart Fail Date: 2010-06-05 Impact factor: 15.534
Authors: Rory O'Hanlon; Agata Grasso; Michael Roughton; James C Moon; Susan Clark; Ricardo Wage; Jessica Webb; Meghana Kulkarni; Dana Dawson; Leena Sulaibeekh; Badri Chandrasekaran; Chiara Bucciarelli-Ducci; Ferdinando Pasquale; Martin R Cowie; William J McKenna; Mary N Sheppard; Perry M Elliott; Dudley J Pennell; Sanjay K Prasad Journal: J Am Coll Cardiol Date: 2010-06-25 Impact factor: 24.094
Authors: Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt Journal: J Am Coll Cardiol Date: 2010-06-25 Impact factor: 24.094
Authors: Carolyn Y Ho; John J V McMurray; Allison L Cirino; Steven D Colan; Sharlene M Day; Akshay S Desai; Steven E Lipshultz; Calum A MacRae; Ling Shi; Scott D Solomon; E John Orav; Eugene Braunwald Journal: Am Heart J Date: 2017-02-16 Impact factor: 4.749
Authors: Joshua G Travers; Fadia A Kamal; Jeffrey Robbins; Katherine E Yutzey; Burns C Blaxall Journal: Circ Res Date: 2016-03-18 Impact factor: 17.367